Decreased risk of new-onset osteoporosis in patients with Type 2 diabetes on SGLT-2 inhibitors
Main finding · Incident osteoporosisResult — go to the resultAdjusted hazard ratio 0.82 95% CI 0.79–0.84Authors' conclusion
In real-world settings, patients with T2D treated with SGLT2is had a lower risk of NOO than those not using SGLT2is.
Study context
- Population
- Patients with T2D, Taiwan's National Health Insurance Research Database, 2016 to 2022matched cohort
- Participants
- 309,747 vs 619,494
- Exposure
- SGLT2i use vs no SGLT2i use
- SGLT2in = 309,747
- Non-SGLT2in = 619,494reference
- Outcome
- New-onset osteoporosis (NOO)
Methodological detailsmatched 1:2 on age, sex and T2D duration, sensitivity analysis with 1:1 propensity score matching
- Matched 1:2 on age, sex and T2D duration
- Sensitivity analysis with 1:1 propensity score matching
Main finding
Incident osteoporosis
Adjusted hazard ratio
0.82
95% CI 0.79–0.84
SGLT2ivs Non-SGLT2i
aHR 0.82 (95% CI 0.79–0.84)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | aHR (95% CI) | |
|---|---|---|
| Osteoporosis, sensitivity analysis with 1:1 propensity score matching | 0.83 (0.80–0.86) | |
| 0.512Adjusted hazard ratio (log scale) |
- Osteoporosis, sensitivity analysis with 1:1 propensity score matching: 274,329 patients per group
Incidence of new-onset osteoporosis (NOO) over time (Kaplan-Meier)
- SGLT2i users had a lower incidence of NOO
Original publication
Decreased risk of new-onset osteoporosis in patients with Type 2 diabetes on SGLT-2 inhibitors. Diabetes Metab. Published 24 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →